Pacific Research Institute CEO on 340B Drug Pricing Program: 'Inject some badly needed transparency into 340B'
Sally Pipes of Pacific Research Institute called for greater congressional oversight and transparency in the federal 340B Drug Pricing Program. Read More »
Alerts Sign-up